<code id='A0C2D2503C'></code><style id='A0C2D2503C'></style>
    • <acronym id='A0C2D2503C'></acronym>
      <center id='A0C2D2503C'><center id='A0C2D2503C'><tfoot id='A0C2D2503C'></tfoot></center><abbr id='A0C2D2503C'><dir id='A0C2D2503C'><tfoot id='A0C2D2503C'></tfoot><noframes id='A0C2D2503C'>

    • <optgroup id='A0C2D2503C'><strike id='A0C2D2503C'><sup id='A0C2D2503C'></sup></strike><code id='A0C2D2503C'></code></optgroup>
        1. <b id='A0C2D2503C'><label id='A0C2D2503C'><select id='A0C2D2503C'><dt id='A0C2D2503C'><span id='A0C2D2503C'></span></dt></select></label></b><u id='A0C2D2503C'></u>
          <i id='A0C2D2503C'><strike id='A0C2D2503C'><tt id='A0C2D2503C'><pre id='A0C2D2503C'></pre></tt></strike></i>

          leisure time

          leisure time

          author:comprehensive    Page View:9973
          IQVIA signage. -- health tech coverage from STAT
          Adobe

          The health data giant IQVIA became a dominant force by gobbling up its rivals. Over decades, it feasted on upstarts with new datasets or novel technologies, growing into a juggernaut with no peer in the business of brokering Americans’ medical information.

          Now, government regulators say, IQVIA’s appetite for acquisition is getting out of control — and must be reined in.

          advertisement

          A Federal Trade Commission lawsuit seeking to block its acquisition of the digital advertising firm DeepIntent marks a crossroads for the company and the multi-billion dollar medical advertising economy it serves. The agency, which is seeking an injunction and temporary restraining order in federal court, argues that IQVIA’s data vault has become so large — and revealing — that it forms the substrate of an entire industry focused on showering doctors and patients with marketing messages.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Readout Newsletter: Bayer study halts, Carmot to IPO, and more
          Readout Newsletter: Bayer study halts, Carmot to IPO, and more

          KenaBetancur/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbi

          read more
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more

          Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

          NovoNordiskviaAPPHILADELPHIA—NovoNordisk’sobesitydrugWegovynotablycuttheriskofheartattacksinalandmar